The Management of Severe Preeclampsia with Intravenous Magnesium Sulphate, Hydralazine and Central Venous Catheterization

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 27, Issue 2, 1987, Pages 102-105

  Red, Leslie L ^a   Ross, Andrew ^a   Kloss, Michael ^a   Paull, John ^a   Markman, Leslie ^a  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYDRALAZINE; MAGNESIUM SULFATE;

CARDIOVASCULAR SYSTEM; CENTRAL VENOUS CATHETERIZATION; CLINICAL ARTICLE; DIAGNOSIS; DRUG THERAPY; FEMALE GENITAL SYSTEM; HUMAN; HYPERTENSION; PREECLAMPSIA; PREGNANCY; THERAPY;

ACUTE DISEASE; CATHETERIZATION, CENTRAL VENOUS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDRALAZINE; INFUSIONS, INTRAVENOUS; MAGNESIUM SULFATE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PROSPECTIVE STUDIES;

EID: 0023221803     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.1987.tb00954.x     Document Type: Article

References (11)

1. Standardised treatment of 154 consecutive cases of eclampsia
2. The clinical and biochemical effects of excess magnesium in the newborn
3. Magnesium sulphate as a tocolytic agent
4. Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy
5. The lupus syndrome induced by hydralazine: a common complication with low dose treatment
6. Hydralazine — is there a safe dose?
7. Antihypertensive effect of plasma volume expansion in pregnancy‐associated hypertension
8. Hemodynamic observations in severe preeclampsia complicated by pulmonary edema
9. Hemodynamic measurements in preeclampsia: preliminary observations